|D012141||Respiratory Tract Infections NIH||0.17|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This is a randomized open label trial to compare effectiveness of two dosing regimens currently used for prevention of clotting events in COVID-19 positive inpatients. Both doses and routes of anticoagulation regimens are currently used in COVID-19 positive inpatients at NYU Langone Health.
Description: 0 = Uninfected; no viral RNA detected Ambulatory = Asymptomatic; viral RNA detected = Symptomatic: Independent = Symptomatic: assistance needed Hospitalized: Mild disease = Hospitalized; no oxygen therapy = Hospitalized; oxygen by mask or nasal prongs = Hospitalized; oxygen by NIV or High flow = Intubation & Mechanical ventilation, pO2/FIO2 >/= 150 or SpO2/FIO2 = Mechanical ventilation pO2/FIO2 < 150 (SpO2/FIO2 <200) 9 = Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis 10 = Dead N (%)Measure: Score on WHO Ordinal Scale Time: 30 days
Description: AKI is defined as any of the following (Not Graded): Increase in SCr by X0.3 mg/dl (X26.5 lmol/l) within 48 hours; or Increase in SCr to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or- Urine volume o0.5 ml/kg/h for 6 hours.Measure: Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI)) Time: 30 days
Description: Measured by troponin and NTproBNPlevelsMeasure: Cardiac injury Time: 30 days
Description: measured by D-dimer and fibrinogen levelsMeasure: Hypercoagulability Time: 30 days
Description: Platelet Count >100 x 109/L 0 Points >50 - <100 x 109/L 1 Point <50 x 109/L 2 Points Increase in Fibrin-related Markers [D Dimers] No change 0 Points Moderate rise 2 Points Strong rise 3 Points Prothrombin Time [PT] Prolongation 3 s or less 0 Points >3 s but <6 s 1 Point >6 s 2 Points Fibrinogen [Clauss] Level >1.0 g/L 0 Points <1.0 g/L 1 Point Score 0-8 Interpretation of Score < 5 Suggestive of non-overt/low grade DIC. Repeat in 1-2 days. ≥ 5 Laboratory evidence consistent with overt DIC.Measure: Disseminated Intravascular Coagulation (DIC) Score Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports